Background/aim: To evaluate the efficacy and toxicity of paclitaxel, gemcitabine, and cisplatin (TGP) as second-line treatment for advanced urothelial carcinoma (UC).
Patients and methods: This study comprised advanced UC progressed after first-line cisplatin-based chemotherapy. Advanced UC was defined as a non-resectable (T4b, any N or any T, or N2-3) or metastatic disease. Twenty-one patients were included in this study. TGP was administered every 3 weeks. The primary endpoint was objective response rate (ORR); the secondary end points were progression-free survival (PFS), overall survival (OS), and toxicity.
Results: The ORR with TGP was 23.8%; the median PFS and OS were 4 and 8.4 months, respectively. The primary side effect was myelosuppression. Grade 3-4 neutropenia and thrombocytopenia were observed in 71.4% and 42.9%, respectively. There were no toxic deaths.
Conclusion: TGP is moderately effective and tolerable as second-line chemotherapy for patients with UC.
Keywords: Advanced urothelial carcinoma; cisplatin; gemcitabine; paclitaxel; second-line chemotherapy.
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.